SavedAdd your journal

Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 3

Systemic Side Effects and Geographic Atrophy after Anti-VEGF Treatment in Wet-Form (Neovascular) Age-Related Macular Degeneration

Yaş Tip (Neovasküler) Yaşa Bağlı Maküla Dejenerasyonunda Anti-VEGF Tedavisi Sonrası Sistemik Sorunlar ve Geografik Atrofi

HARUN ÇAKMAK
Sema ORUÇ DÜNDAR
Pages
256–261
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Systemic side effects and geographic atrophy following intravitreal administration of anti-VEGF agents in nARMD are mentioned in this review

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neovascular (wet-form) age-related macular degeneration (nARMD) is one of the leading causes of serious loss of vision in elderly population.
📊
Key Findings & Data:Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents are commonly used in the treatment of nARMD.
💡
Conclusion & Impact:Systemic side effects and geographic atrophy following intravitreal administration of anti-VEGF agents in nARMD are mentioned in this review
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neovascular (wet-form) age-related macular degeneration (nARMD) is one of the leading causes of serious loss of vision in elderly population. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents are commonly used in the treatment of nARMD. Systemic side effects and geographic atrophy following intravitreal administration of anti-VEGF agents in nARMD are mentioned in this review

Özet

Neovasküler (yaş tip) yaşa bağlı maküla dejenerasyonu (nYBMD) ileri yaşta görmenin ciddi şekilde azalmasının en başta gelen nedenlerinden birisidir. nYBMD tedavisinde intravitreal anti vasküler endotelyal growth faktör (anti-VEGF) ajanlar yaygın olarak kullanılmaktadır. Bu derlemede nYBMD'de anti-VEGF ajanların intravitreal uygulanımı sonrası meydana gelebilen sistemik sorunlar ve geografik atrofiden bahsedilmiştir

🔖

Cite This Article

ÇAKMAK, H., DÜNDAR, S. O. (2017). Systemic Side Effects and Geographic Atrophy after Anti-VEGF Treatment in Wet-Form (Neovascular) Age-Related Macular Degeneration. Güncel Retina Dergisi, Cilt: 1 - Sayı: 3, 256–261. https://ajindex.com/articles/198378

References (10)

  1. Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM ve ark. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116(11):2141-8
  2. Bock F, Konig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C. Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe. 2007;104:336–44
  3. Dastjerdi MH, Saban DR, Okanobo A, Nallasamy N, Sadrai Z, Chauhan SK ve ark. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2010;51:2411–7
  4. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6):502-8
  5. Andrés-Guerrero V, Perucho-González L, García-Feijoo J, Morales-Fernández L, Saenz-Francés F, Herrero-Vanrell R ve ark. Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. Adv Ther. 2017 34(2):378-395
  6. Raser HM, Wilson H, Rudge JS, Wiegand S. Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function. J Clin Endocrinol Metab. 2005;90(2):1114-22 7. Thanasopoulos AN, Schneider D, Keiper T, Thanasopoulos AN, Schneider D, Keiper T, ve ark. Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing. J Biol Chem. 2007;282(37):26746-5 8. Affert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D ve ark. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290(2):547-59
  7. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh. VEGF receptor signalling in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359-7
  8. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N ve ark. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171(1):53-6
  9. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69 (Suppl 3):25-3
  10. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F ve ark. Arterial Thromboembolic events in patients with metastatic carcinoma treated with chemo